Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer
Recruiting
Observational Study
Lung Cancer, Non-Small Cell
Immunotherapy
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 79
- Sex
- Any
- Study type
- Observational
- Participants needed
- 500 (estimated)
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this observational study is to learn about the long-term effects of neoadjuvant immunotherapy in patients with lung cancer. The main questions it aims to answer are:
* Does pneumonectomy bring more benefits for pateints than lobectomy?
* Does surgery bring more benefits for patients than non-surgery modalities (such as radiotherapy) after neoadjuvnat immunotherapy? Participants will r…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Aged between 18 and 79 years;
2. Received at least two cycles of neoadjuvant immunotherapy;
3. ECOG performance status score of 0;
4. Complete clinical information including imaging data available.
Exclusion Criteria:
1. Diagnosed with or suspected active autoimmune disease…
Contacts